Abstract

Phyllodes tumors of breast, even histologically diagnosed as benign, can recur locally and have metastatic potential. Histologic markers only have limited value in predicting the clinical behavior of phyllodes tumors. It remains unknown what drives the malignant progression of phyllodes tumors. We found that the expression of myofibroblast markers, α-smooth muscle actin (α-SMA), fibroblast activation protein (FAP), and stromal cell-derived factor-1 (SDF-1), is progressively increased in the malignant progression of phyllodes tumors. Microarray showed that miR-21 was one of the most significantly upregulated microRNAs in malignant phyllodes tumors compared with benign phyllodes tumors. In addition, increased miR-21 expression was primarily localized to α-SMA-positive myofibroblasts. More importantly, α-SMA and miR-21 are independent predictors of recurrence and metastasis, with their predictive value of recurrence better than histologic grading. Furthermore, miR-21 mimics promoted, whereas miR-21 antisense oligos inhibited, the expression of α-SMA, FAP, and SDF-1, as well as the proliferation and invasion of primary stromal cells of phyllodes tumors. The ability of miR-21 to induce myofibroblast differentiation was mediated by its regulation on Smad7 and PTEN, which regulate the migration and proliferation, respectively. In breast phyllodes tumor xenografts, miR-21 accelerated tumor growth, induced myofibroblast differentiation, and promoted metastasis. This study suggests an important role of myofibroblast differentiation in the malignant progression of phyllodes tumors that is driven by increased miR-21.

Highlights

  • Phyllodes tumors of the breast are typically large and fast growing tumors that accounts for up to 1% of all breast neoplasms [1]

  • To investigate whether myofibroblast differentiation is associated with malignant progression of phyllodes tumors, we examined the presence of myofibroblasts in 268 phyllodes tumor samples, including 167 benign, 36 borderline, and 65 malignant phyllodes tumors

  • To confirm the myofibroblast markers are overexpressed in the stromal cells of phyllodes tumors, we measured the mRNA and protein levels of a-smooth muscle actin (a-SMA), fibroblast activation protein (FAP), and stromal cell–derived factor-1 (SDF-1) in the primary stromal cells isolated from normal breast tissue, fibroadenoma, benign, borderline, and malignant phyllodes tumors with eight cases per group

Read more

Summary

Introduction

Phyllodes tumors of the breast are typically large and fast growing tumors that accounts for up to 1% of all breast neoplasms [1]. Many phyllodes tumors tend to behave in a benign manner, the clinical outcome of phyllodes tumors is hard to predict, with frequent local relapse and sometimes distant metastasis. Current approach to prevent recurrence and metastasis is surgical resection with wide margin, given that adjuvant chemotherapy or radiotherapy is. Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/).

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call